In silico prediction of cytochrome P450-mediated site of metabolism (SOM)

Protein and Peptide Letters

Volumn 20, Issue 3, 2013, Pages 279-289

  Liu, Xian ^a   Shen, Qiancheng ^a   Li, Jing ^a   Li, Shanshan ^a   Luo, Cheng ^a   Zhu, Weiliang ^a   Luo, Xiaomin ^a   Zheng, Mingyue ^a   Jiang, Hualiang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

ADME; Computational method; CYP; Cytochrome P450; SOM

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4;

ACCURACY; ARTICLE; CALCULATION; COMPUTER MODEL; DRUG METABOLISM; ENZYME METABOLISM; ENZYME STRUCTURE; ENZYME SUBSTRATE; KNOWLEDGE BASE; LIGAND BINDING; METABOLIC PARAMETERS; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SITE OF METABOLISM; SYSTEMS BIOLOGY;

EID: 84877939185     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/0929866511320030006     Document Type: Article

References (113)

1. Zhang, S. Computer-Aided Drug Discovery and Development. In: Drug Design and Discovery: Methods and Protocols, Satyanarayanajois, S.D., Ed.; Humana Press Inc., 2011; pp. 23-38.
2. Schneider, G.; Fechner, U. Computer-based de novo design of drug-like molecules. Nat. Rev. Drug Discov., 2005, 4(8), 649-663.
3. Caldwell, G.W.; Yan, Z.Y.; Tang, W.M.; Dasgupta, M.; Hasting, B. ADME optimization and toxicity assessment in early- and latephase drug discovery. Curr. Top. Med. Chem., 2009, 9(11), 965-980.
4. Gola, J.; Obrezanova, O.; Champness, E.; Segall, M. ADMET property prediction: The state of the art and current challenges. QSAR Comb. Sci., 2006, 25(12), 1172-1180.
5. van de Waterbeemd, H.; Gifford, E. ADMET in silico modelling: Towards prediction paradise? Nat. Rev. Drug Discov., 2003, 2(3), 192-204.
6. Baillie, T.A. Future of toxicology-metabolic activation and drug design: Challenges and opportunities in chemical toxicology. Chem. Res. Toxicol., 2006, 19(7), 889-893.
7. Li, A.P.; Kaminski, D.L.; Rasmussen, A. Substrates of human hepatic cytochrome P450 3A4. Toxicology, 1995, 104(1-3), 1-8.
8. Yap, C.W.; Chen, Y.Z. Prediction of cytochrome p450 3A4, 2D6, and 2C9 inhibitors and substrates by using support vector machines. J. Chem. Inf. Model., 2005, 45(4), 982-992.
9. Guengerich, F.P.; Parikh, A. Expression of drug-metabolizing enzymes. Curr. Opin. Biotech., 1997, 8(5), 623-628.
10. Wienkers, L.C.; Heath, T.G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov., 2005, 4(10), 825-833.
11. Lee, S.; Kim, D. Cytochrome P450 networks in chemical space. Arch. Pharm. Res., 2010, 33(9), 1361-1374.
12. Schlichting, I.; Berendzen, J.; Chu, K.; Stock, A.M.; Maves, S.A.; Benson, D.E.; Sweet, B.M.; Ringe, D.; Petsko, G.A.; Sligar, S.G. The catalytic pathway of cytochrome P450cam at atomic resolution. Science, 2000, 287(5458), 1615-1622.
13. Denisov, I.G.; Makris, T.M.; Sligar, S.G.; Schlichting, I. Structure and chemistry of cytochrome P450. Chem. Rev., 2005, 105(6), 2253-2277.
14. Williams, J.A.; Hyland, R.; Jones, B.C.; Smith, D.A.; Hurst, S.; Goosen, T.C.; Peterkin, V.; Koup, J.R.; Ball, S.E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUC(i)/AUC) ratios. Drug Metab. Dispos., 2004, 32 (11), 1201-1208.
15. de Groot, M.J. Designing better drugs: predicting cytochrome P450 metabolism. Drug Discov. Today, 2006, 11(13-14), 601-606.
16. Smith, D.A.; Jones, B.C. Speculations on the substrate structure activity relationship (ssar) of Cytochrome-P450 enzymes. Biochem. Pharmacol., 1992, 44(11), 2089-2098.
17. Anzenbacher, P.; Anzenbacherova, E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol. Life Sci., 2001, 58(5-6), 737-747.
18. Sun, H.; Scott, D.O. Structure-based drug metabolism predictions for drug design. Chem. Biol. Drug Des., 2010, 75(1), 3-17.
19. Wang, J.F.; Chou, K.C. Molecular modeling of cytochrome P450 and drug metabolism.Curr. Drug. Mrtab., 2010, 11 (4), 342-346.
20. Emoto, C.; Murayama, N.; Rostami-Hodjegan, A.; Yamazaki, H. Methodologies for investigating drug metabolism at the early drug discovery stage: Prediction of hepatic drug clearance and P450 contribution. Curr. Drug Mrtab., 2010, 11(8), 678-685.
21. Porter, T.D.; Coon, M.J. Cytochrome-P-450 - Multiplicity of Isoforms, Substrates, and Catalytic and Regulatory Mechanisms. J. Biol. Chem., 1991, 266(21), 13469-13472.
22. Vermeulen, N.P.E.; de Graaf, C.; Feenstra, K.A. Cytochrome P450 in silico: An integrative modeling approach. J. Med. Chem., 2005, 48(8), 2725-2755.
23. Shaik, S.; Kumar, D.; de Visser, S.P.; Altun, A.; Thiel, W. Theoretical perspective on the structure and mechanism of cytochrome P450 enzymes. Chem. Rev., 2005, 105(6), 2279-2328.
24. Rendic, S.; Guengerich, F.P. Special issue on human cytochromes P450 (human CYPs) Human cytochrome P450 enzymes, a status report summarizing their reactions, substrates, inducers, and inhibitors - 1st update - Foreword. Drug Metab. Rev., 2002, 34(1- 2), Ix-X.
25. Zhou, S.F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Mrtab., 2008, 9(4), 310-322.
26. Rendic, S.; DiCarlo, F.J. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev., 1997, 29(1-2), 413-580.
27. Zhou, S.F.; Zhou, Z.W.; Yang, L.P.; Cai, J.P. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr. Med. Chem., 2009, 16(27), 3480-3675.
28. Zaretzki, J.; Bergeron, C.; Bennett, K.; Breneman, C.M. A novel method for predicting ligand regioselectivity to metabolism by cyp p450 enzymes. Abstr. Pap. Am. Chem. Soc., 2009, 237.
29. Clark, D.S.; Traylor, M.J.; Chai, J. Simultaneous measurement of CYP1A2 activity, regioselectivity, and coupling: Implications for environmental sensitivity of enzyme-substrate binding. Arch. Biochem. Biophys., 2011, 505(2), 186-193.
30. Hasegawa, K.; Koyama, M.; Funatsu, K. Quantitative Prediction of Regioselectivity Toward Cytochrome P450/3A4 Using Machine Learning Approaches. Mol. Inform., 2010, 29(3), 243-249.
31. No, K.T.; Jung, J.; Kim, N.D.; Kim, S.Y.; Choi, I.; Cho, K.H.; Oh, W.S.; Kim, D.N. Regioselectivity prediction of CYP1A2-mediated phase I metabolism. J. Chem. Inf. Model., 2008, 48(5), 1074-1080.
32. No, K.T.; Oh, W.S.; Kim, D.N.; Jung, J.; Cho, K.H. New combined model for the prediction of regioselectivity in cytochrome P450/3A4 mediated metabolism. J. Chem. Inf. Model., 2008, 48(3), 591-601.
33. Shaik, S.; de Visser, S.P.; Ogliaro, F.; Sharma, P.K. What factors affect the regioselectivity of oxidation by cytochrome P450? A DFT study of allylic hydroxylation and double bond epoxidation in a model reaction. J. Am. Chem. Soc., 2002, 124(39), 11809-11826.
34. Sheridan, R.P.; Korzekwa, K.R.; Torres, R.A.; Walker, M.J. Empirical regioselectivity models for human cytochromes p450 3A4, 2D6, and 2C9. J. Med. Chem., 2007, 50(14), 3173-3184.
35. Vermeulen, N.P.E.; Keizers, P.H.J.; de Graaf, C.; de Kanter, F.J.J.; Oostenbrink, C.; Feenstra, K.A.; Commandeur, J.N.M. Metabolic regio- and stereoselectivity of cytochrome P450 2D6 towards 3,4- methylenedioxy-N- alkylamphetamines: in silico predictions and experimental validation. J. Med. Chem., 2005, 48(19), 6117-6127.
36. Lu, H. Stereoselectivity in drug metabolism. Expert Opin. Drug Metab. Toxicol., 2007, 3(2), 149-158.
37. Kayser, O.; Julsing, M.K.; Vasilev, N.P.; Schneidman-Duhovny, D.; Muntendarn, R.; Woerdenbag, H.J.; Quax, W.J.; Wolfson, H.J.; Ionkova, I. Metabolic stereoselectivity of cytochrome P450 3A4 towards deoxypodophyllotoxin: In silico predictions and experimental validation. Eur. J. Med. Chem., 2008, 43(6), 1171-1179.
38. Pastor, M.; Cruciani, G.; McLay, I.; Pickett; Clementi, S. GRid-in dependent descriptors (GRIND): A novel class of alignmentindependent three-dimensional molecular descriptors. J. Med. Chem., 2000, 251-260.
39. Korzekwa, K.R.; Grogan, J.; DeVito, S.; Jones, J.P. Electronic models for cytochrome P450 oxidations. Adv. Exp. Med. Biol., 1996, 387, 361-369.
40. de Groot, M.J.; Ackland, M.J.; Horne, V.A.; Alex, A.A.; Jones, B.C. Novel approach to predicting P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for CYP2D6. J. Med. Chem., 1999, 42(9), 1515-1524.
41. Mancy, A.; Broto, P.; Dijols, S.; Dansette, P.M.; Mansuy, D. The substrate-binding site of human liver Cytochrome-P450 2C9 - an approach using designed Tienilic acid-derivatives and molecular modeling. Biochemistry-Us, 1995, 34(33), 10365-10375.
42. de Visser, S.P.; Ogliaro, F.; Sharma, P.K.; Shaik, S. What factors affect the regioselectivity of oxidation by cytochrome P450? A DFT study of allylic hydroxylation and double bond epoxidation in a model reaction. J. Am. Chem. Soc., 2002, 124(39), 11809-11826.
43. de Groot, M.J.; Ackland, M.J.; Horne, V.A.; Alex, A.A.; Jones, B.C. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J. Med. Chem., 1999, 42(20), 4062-4070.
44. Tarcsay, A.; Keseru, G.M. In silico site of metabolism prediction of cytochrome P450-mediated biotransformations. Expert Opin. Drug Metab. Toxicol., 2011, 7(3), 299-312.
45. Zhang, T.; Chen, Q.; Li, L.; Liu, L.A.; Wei, D.Q. In silico prediction of Cytochrome P450-mediated drug metabolism.Comb. Chem. High T. Scr., 2011, 14(5), 388-395.
46. Dudek, A.Z.; Arodz, T.; Galvez, J. Computational methods in developing quantitative structure-activity relationships (QSAR): A review. Comb. Chem. High T. Scr., 2006, 9(3), 213-228.
47. Bottegoni, G. Protein-ligand docking. Front Biosci., 2011, 16, 2289-2306.
48. Jorgensen, W.L. The many roles of computation in drug discovery. Science, 2004, 303(5665), 1813-1818.
49. Rosales-Hernandez, M.C.; Mendieta-Wejebe, J.E.; Trujillo-Ferrara, J.G.; Correa-Basurto, J. Homology modeling and molecular dynamics of CYP1A1 and CYP2B1 to explore the metabolism of aryl derivatives by docking and experimental assays. Eur. J. Med. Chem., 2010, 45(11), 4845-4855.
50. Kanth, B.K.; Liou, K.; Sohng, J.K. Homology modeling, binding site identification and docking in flavone hydroxylase CYP105P2 in Streptomyces peucetius ATCC 27952. Comput. Biol. Chem., 2010, 34(4), 226-231.
51. Wester, M.R.; Johnson, E.F.; Marques-Soares, C.; Dansette, P.M.; Mansuy, D.; Stout, C.D. Structure of a substrate complex of mammalian cytochrome P4502C5 at 2.3 angstrom resolution: Evidence for multiple substrate binding modes. Biochemistry-Us, 2003, 42 (21), 6370-6379.
52. Williams, P.A.; Cosme, J.; Ward, A.; Angova, H.C.; Vinkovic, D.M.; Jhoti, H. Crystal structure of human cytochrome P4502C9 with bound warfarin. Nature, 2003, 424(6947), 464-468.
53. Afzelius, L.; Arnby, C.H.; Broo, A.; Carlsson, L.; Isaksson, C.; Jurva, U.; Kjellander, B.; Kolmodin, K.; Nilsson, K.; Raubacher, F.; Weidolf, L. State-of-the-art tools for computational site of metabolism predictions: Comparative analysis, mechanistical insights, and future applications. Drug Metab. Rev., 2007, 39(1), 61-86.
54. Irwin, J.J.; Shoichet, B.K.; Mysinger, M.M.; Coleman, R.G.; Carchia, M.; Nguyen, K.T. DOCK 3.5.54: Advances in the last 6 years, and benchmarking results. Abstr. Pap. Am. Chem. Soc., 2011, 241, 111-COMP.
55. de Graaf, C.; Oostenbrink, C.; Keizers, P.H.J.; van der Wijst, T.; Jongejan, A.; Vemleulen, N.P.E. Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J. Med. Chem., 2006, 49(8), 2417-2430.
56. Jones, G.; Willett, P.; Glen, R.C.; Leach, A.R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol., 1997, 267(3), 727-748.
57. Vermeulen, N.P.E.; de Graaf, C.; Pospisil, P.; Pos, W.; Folkers, G. Binding mode prediction of cytochrome P450 and thymidine kinase protein-ligand complexes by consideration of water and rescoring in automated docking. J. Med. Chem., 2005, 48(7), 2308-2318.
58. Kroemer, R. T. Structure-based drug design: Docking and scoring. Curr. Protein Pept. Sci., 2007, 8(4), 312-328.
59. Kitchen, D.B.; Decornez, H.; Furr, J.R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: Methods and applications. Nat. Rev. Drug Discov., 2004, 3(11), 935-949.
60. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K.; Shaw, D.E.; Francis, P.; Shenkin, P.S. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem., 2004, 47(7), 1739-1749.
61. Halgren, T.A.; Murphy, R.B.; Friesner, R.A.; Beard, H.S.; Frye, L.L.; Pollard, W.T.; Banks, J.L. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem., 2004, 47(7), 1750-1759.
62. Zhou, D.S.; Afzelius, L.; Grimm, S.W.; Andersson, T.B.; Zauhar, R.J.; Zamora, I. Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions. Drug Metab. Dispos., 2006, 34(6), 976-983.
63. Tarcsay, A.; Kiss, R.; Keseru, G.M. Site of metabolism prediction on cytochrome P450 2C9: a knowledge-based docking approach. J. Comput.-Aided Mol. Des., 2010, 24(5), 399-408.
64. Nussinov, R.; Ma, B.Y.; Shatsky, M.; Wolfson, H.J. Multiple diverse ligands binding at a single protein site: A matter of preexisting populations. Protein Sci., 2002, 11(2), 184-197.
65. Miller, G.P.; Hanna, I.H.; Nishimura, Y.; Guengerich, F.P. Oxidation of phenethylamine derivatives by cytochrome P450 2D6: The issue of substrate protonation in binding and catalysis. Biochemistry-Us, 2001, 40(47), 14215-14223.
66. Hritz, J.; de Ruiter, A.; Ostenbrink, C. Impact of plasticity and flexibility on docking results for Cytochrome P450 2D6: A combined approach of molecular dynamics and ligand docking. J. Med. Chem., 2008, 51(23), 7469-7477.
67. Keizers, P.H.; de Graaf, C.; de Kanter, F.J.; Oostenbrink, C.; Feenstra, K.A.; Commandeur, J.N.; Vermeulen, N.P. Metabolic regio- and stereoselectivity of cytochrome P450 2D6 towards 3,4- methylenedioxy-N-alkylamphetamines: in silico predictions and experimental validation. J. Med. Chem., 2005, 48(19), 6117-6127.
68. De Benedetti, P.G.; Fanelli, F. Computational quantum chemistry and adaptive ligand modeling in mechanistic QSAR. Drug Discov. Today, 2010, 15(19-20), 859-866.
69. Bugrim, A.; Nikolskaya, T.; Nikolsky, Y. Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Discov. Today, 2004, 9(3), 127-135.
70. Karelson, M.; Lobanov, V.S.; Katritzky, A.R. Quantum-chemical descriptors in QSAR/QSPR studies. Chem. Rev., 1996, 96(3), 1027-1043.
71. Shaik, S.; Cohen, S.; Wang, Y.; Chen, H.; Kumar, D.; Thiel, W. P450 Enzymes: Their structure, reactivity, and selectivity-modeled by QM/MM calculations. Chem. Rev., 2010, 110(2), 949-1017.
72. Singh, S.B.; Shen, L.Q.; Walker, M.J.; Sheridan, R.P. A model for predicting likely sites of CYP3A4-mediated metabolism on druglike molecules. J. Med. Chem., 2003, 46(8), 1330-1336.
73. No, K.T.; Kim, D.N.; Cho, K.H.; Oh, W.S.; Lee, C.J.; Lee, S.K.; Jung, J. E(a)MEAD: Activation energy prediction of Cytochrome P450 mediated metabolism with effective atomic descriptors. J. Chem. Inf. Model., 2009, 49(7), 1643-1654.
74. Jiang, H.L.; Zheng, M.Y.; Luo, X.M.; Shen, Q.C.; Wang, Y.; Du, Y.; Zhu, W.L. Site of metabolism prediction for six biotransformations mediated by cytochromes P450. Bioinformatics, 2009, 25(10), 1251-1258.
75. Smith, J.; Stein, V. SPORCalc: A development of a database analysis that provides putative metabolic enzyme reactions for ligand-based drug design. Comput. Biol. Chem., 2009, 33(2), 149-159.
76. Boyer, S.; Arnby, C.H.; Carlsson, L.; Smith, J.; Stein, V.; Glen, R.C. Reaction site mapping of xenobiotic biotransformations. J. Chem. Inf. Model, 2007, 47(2), 583-590.
77. Sun, J.; Li, H.Y.; Fan, X.W.; Sui, X.F.; Zhang, L.; Wang, Y.J.; He, Z.G. Considerations and recent advances in QSAR models for cytochrome P450-mediated drug metabolism prediction. J. Comput.-Aided Mol. Des., 2008, 22(11), 843-855.
78. Chau, M.; Chen, H.A machine learning approach to web page filtering using content and structure analysis. Decis. Support. Syst., 2008, 44(2), 482-494.
79. Gasteiger, J.; Terfloth, L.; Bienfait, B. Ligand-based models for the isoform specificity of cytochrome P450 3A4, 2D6, and 2C9 substrates. J. Chem. Inf. Model, 2007, 47(4), 1688-1701.
80. Wang, D.; Zhang, Y.L.; Qiao, Y.J. Support vector machine and Kstar models predict the o-dealkylation reaction mediated by Cytochrome P450. Acta Physico-Chimica. Sinica, 2011, 27(2), 343-351.
81. Zhu, J.; Kulkarni, S.A.; Blechinger, S. In silico techniques for the study and prediction of xenobiotic metabolism: A review. Xenobiotica, 2005, 35(10-11), 955-973.
82. Cruciani, G.; Carosati, E.; De Boeck, B.; Ethirajulu, K.; Mackie, C.; Howe, T.; Vianello, R. MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist. J. Med. Chem., 2005, 48(22), 6970-6979.
83. Klopman, G.; Dimayuga, M.; Talafous, J. A Program for the evaluation of metabolic transformation of chemicals. J. Chem. Inf. Comp. Sci., 1994, 34(6), 1320-1325.
84. Talafous, J.; Sayre, L.M.; Mieyal, J.J.; Klopman, G. A dictionary model of mammalian xenobiotic metabolism. J. Chem. Inf. Comp. Sci., 1994, 34(6), 1326-1333.
85. Klopman, G.; Tu, M.H.; Talafous, J. A genetic algorithm for metabolic transform priorities optimization. J. Chem. Inf. Comp. Sci.,1997, 37(2), 329-334.
86. Darvas, F.; Keseru, G.; Papp, A.; Dorman, G.; Urge, L.; Krajcsi, P. In silico and ex silico ADME approaches for drug discovery. Curr. Top. Med. Chem., 2002, 2(12), 1287-1304.
87. Button, W.G.; Judson, P.N.; Long, A.; Vessey, J.D. Using absolute and relative reasoning in the prediction of the potential metabolism of xenobiotics. J. Chem. Inf. Comp. Sci., 2003, 43(5), 1371-1377.
88. Ekins, S.; Mestres, J.; Testa, B. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Brit. J. Pharmacol., 2007, 152(1), 9-20.
89. CompuDrug; 2010. Available from: www.compudrug.com.
90. Hosea, N.A. Drug design tools - in silico, in vitro and in vivo ADME/PK prediction and interpretation: Is PK in monkey an essential part of a good human PK prediction? Curr. Top. Med. Chem., 2011, 11(4), 351-357.
91. Le, H.; Shin, Y.; Hop, C.; Khojasteh, C. Comparison of in silico tools for the prediction of sites of metabolism by cytochrome P450. Drug Metab. Rev., 2010, 42, 186-186.
92. Gopaul, V.S.; Shin, Y.; Le, H.; Baumgardner, M.; Hop, C.; Khojasteh, C. Comparison of metasite and stardrop prediction of CYP3A4, CYP2C9 and CYP2D6. Drug Metab. Rev., 2009, 41, 119-119.
93. Olsen, L.; Rydberg, P.; Rod, T.H.; Ryde, U. Prediction of activation energies for hydrogen abstraction by cytochrome P450. J. Med. Chem., 2006, 49(22), 6489-6499.
94. Olsen, L.; Rydberg, P.; Ryde, U. Prediction of Activation Energies for Aromatic Oxidation by Cytochrome P450. J. Phys. Chem. A, 2008, 112(50), 13058-13065.
95. Olsen, L.; Rydberg, P.; Vasanthanathan, P.; Oostenbrink, C. Fast prediction of Cytochrome P450 mediated drug metabolism. Chemmedchem., 2009, 4(12), 2070-2079.
96. Olsen, L.; Rydberg, P.; Gloriam, D.E.; Zaretzki, J.; Breneman, C. SMARTCyp: A 2D Method for Prediction of Cytochrome P450- Mediated Drug Metabolism. Acs. Med. Chem. Lett., 2010, 1(3), 96-100.
97. Long, A.; Walker, J.D. Quantitative structure-activity relationships for predicting metabolism and modeling cytochrome P450 enzyme activities. Environ. Toxicol. Chem., 2003, 22(8), 1894-1899.
98. Zuegge, J.; Fechner, U.; Roche, O.; Parrott, N.J.; Engkvist, O.; Schneider, G. A fast virtual screening filter for cytochrome P450 3A4 inhibition liability of compound libraries. Quant. Struct-Act. Rel., 2002, 21(3), 249-256.
99. Smith, D.A.; Ackland, M.J.; Jones, B.C. Properties of cytochrome P450 isoenzymes and their substrates .2. properties of cytochrome P450 substrates. Drug Discov. Today, 1997, 2(11), 479-486.
100. Smith, D.A.; Ackland, M.J.; Jones, B.C. Properties of cytochrome P450 isoenzymes and their substrates .1. active site characteristics. Drug Discov. Today, 1997, 2(10), 406-414.
101. Sjogren, T.; Ekroos, M. Structural basis for ligand promiscuity in cytochrome P450 3A4. P. Natl. Acad. Sci. USA, 2006, 103(37), 13682-13687.
102. ROCS, version 2.2; Openeye Scientic Software:Santa Fe, NM, 2006.
103. Sykes, M.J.; McKinnon, R.A.; Miners, J.O. Prediction of metabolism by cytochrome P4502C9: Alignment and docking studies of a validated database of substrates. J. Med. Chem., 2008, 51(4), 780-791.
104. Forsythe, I.J.; Wishart, D.S. Exploring human metabolites using the human metabolome database. Curr. protocols in bioinformatics, 2009, Chapter 14, Unit14.18.
105. Hildebrandt, C.; Wolf, S.; Neumann, S. Database supported candidate search for metabolite identification. J. Integr. Bioinformatics, 2011, 8(2), 157.
106. Baurin, N.; Baker, R.; Richardson, C.; Chen, I.; Foloppe, N.; Potter, A.; Jordan, A.; Roughley, S.; Parratt, M.; Greaney, P.; Morley, D.; Hubbard, R.E. Drug-like annotation and duplicate analysis of a 23-supplier chemical database totalling 2.7 million compounds. J. Chem. Inf. Comp. Sci., 2004, 44(2), 643-651.
107. Miteva, M.A.; Violas, S.; Montes, M.; Gomez, D.; Tuffery, P.; Villoutreix, B.O. FAF-Drugs: free ADME/tox filtering of compound collections. Nucleic. Acids Res., 2006, 34, W738-W744.
108. Langowski, J.; Long, A. Computer systems for the prediction of xenobiotic metabolism. Adv. Drug Deliv. Rev., 2002, 54(3), 407-415.
109. Korolev, D.; Balakin, K.V.; Nikolsky, Y.; Kirillov, E.; Ivanenkov, Y.A.; Savchuk, N.P.; Ivashchenko, A.A.; Nikolskaya, T. Modeling of human cytochrome P450-mediated drug metabolism using unsupervised machine learning approach. J. Med. Chem., 2003, 46(17), 3631-3643.
110. Keseru, G.M.; Molnar, L. METAPRINT: A metabolic fingerprint. Application to cassette design for high-throughput ADME screening. J. Chem. Inf. Comp. Sci., 2002, 42(2), 437-444.
111. Ekins, S.; Andreyev, S.; Ryabov, A.; Kirillov, E.; Rakhmatulin, E.A.; Bugrim, A.; Nikolskaya, T. Computational prediction of human drug metabolism. Expert Opin. Drug Metab., 2005, 1(2), 303-324.
112. Erhardt, P.W. A human drug metabolism database: Potential roles in the quantitative predictions of drug metabolism and metabolismrelated drug-drug interactions.Curr. Drug Mrtab., 2003, 4(5), 411-422.
113. Zamora, I.; Afzelius, L.; Cruciani, G. Predicting drug metabolism: A site of metabolism prediction tool applied to the cytochrome P4502C9. J. Med. Chem., 2003, 46(12), 2313-2324.